Datasets:
chunk_id stringlengths 23 27 | chunk stringlengths 40 4.57k | source_url stringclasses 246
values | title stringclasses 246
values | chunk_idx int64 0 68 | chunk_start_char int64 0 20.9k | chunk_end_char int64 49 21k |
|---|---|---|---|---|---|---|
0000051434-25-000060#s65 | On August 20, 2025, International Paper Company (the “ Company ”) committed to mill closures at its Riceboro, Georgia and Savannah, Georgia facilities impacting its Containerboard business. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 0 | 65 | 254 |
0000051434-25-000060#s255 | The Company estimates the closures will result in aggregate pre-tax cash charges of approximately $158 million and pre-tax non-cash accelerated depreciation charges of approximately $570 million as further described below. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 1 | 255 | 287 |
0000051434-25-000060#s478 | These actions are being undertaken as part of the Company’s 80/20 strategic approach, as announced by the Company in July 2024. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 2 | 478 | 192 |
0000051434-25-000060#s606 | Through the 80/20 strategic approach, we intend to deliver profitable market share growth by striving to be the lowest-cost producer and the most reliable and innovative sustainable packaging solutions provider to our customers across North America and EMEA. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 3 | 606 | 864 |
0000051434-25-000060#s865 | As part of the Company’s 80/20 strategic approach, the Company intends to guide investments and align resources to win with our most strategic customers, while reducing complexity and cost across the Company. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 4 | 865 | 814 |
0000051434-25-000060#s1074 | Riceboro, Georgia Mill The Company plans to permanently close its containerboard, timber and lumber mills in Riceboro, Georgia. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 5 | 1,074 | 1,201 |
0000051434-25-000060#s1202 | The containerboard mill will shut down in stages with all operations expected to cease by September 12, 2025. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 6 | 1,202 | 1,183 |
0000051434-25-000060#s1312 | The closure is expected to reduce the Company’s containerboard capacity by approximately 430,000 tons. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 7 | 1,312 | 1,176 |
0000051434-25-000060#s1415 | The Company estimates that the closure will result in aggregate pre-tax noncash asset write-off and accelerated depreciation charges of approximately $170 million and aggregate pre-tax cash severance and other shutdown charges of approximately $77 million, and anticipates that these charges will be recorded during the ... | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 8 | 1,415 | 1,433 |
0000051434-25-000060#s1775 | The Company expects closure of the containerboard mill to reduce its workforce by approximately 300 employees. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 9 | 1,775 | 1,184 |
0000051434-25-000060#s1886 | Savannah, Georgia Mill The Company plans to permanently close its containerboard mill and packaging facility in Savannah, Georgia. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 10 | 1,886 | 2,016 |
0000051434-25-000060#s2017 | The containerboard mill will shut down in stages with all operations expected to cease by September 30, 2025. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 11 | 2,017 | 1,995 |
0000051434-25-000060#s2127 | The closure is expected to reduce the Company’s containerboard capacity by approximately 1,000,000 tons. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 12 | 2,127 | 1,990 |
0000051434-25-000060#s2232 | The Company estimates that the closure will result in aggregate pre-tax noncash asset write-off and accelerated depreciation charges of approximately $400 million and aggregate pre-tax cash severance and other shutdown charges of approximately $81 million, and anticipates that these charges will be recorded during the ... | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 13 | 2,232 | 2,245 |
0000051434-25-000060#s2592 | The Company expects closure of the containerboard mill to reduce its workforce by approximately 680 employees. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 14 | 2,592 | 1,996 |
0000051434-25-000060#s2737 | The disclosure under Item 2.05 is incorporated by reference into this item 2.06. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 15 | 2,737 | 2,817 |
0000051434-25-000060#s2859 | On August 21, 2025, the Company issued a press release announcing these actions, which is attached as Exhibit 99.1 and is incorporated herein by reference. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 16 | 2,859 | 3,014 |
0000051434-25-000060#s3015 | The information furnished pursuant to this Item 7.01, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the ... | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 17 | 3,015 | 3,409 |
0000051434-25-000060#s3439 | This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding, among other things, our closures and associated headcount reduction as well as anticipated expense reductions, the expected amount of certain pre-tax cha... | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 18 | 3,439 | 3,882 |
0000051434-25-000060#s3883 | These forward-looking statements reflect management's current views and are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from those expressed or implied in these forward-looking statements. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 19 | 3,883 | 3,696 |
0000051434-25-000060#s4141 | Factors which could cause actual results to differ from such forward-looking statements include, but are not limited to, industry, global, economic and other conditions, as well as other factors, that could affect the closures including the amount of such pre-tax charges and the timing of such pre-tax charges or action... | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 20 | 4,141 | 3,778 |
0000051434-25-000060#s4481 | These forward-looking statements are also subject to the risks and uncertainties relating to the business of the Company contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 21, 2025, the Company... | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 21 | 4,481 | 3,987 |
0000051434-25-000060#s5030 | In addition, other risks and uncertainties not presently known to the Company or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 22 | 5,030 | 3,623 |
0000051434-25-000060#s5215 | The Company undertakes no obligation to publicly update any forward-looking statements contained in this Current Report on Form 8-K, whether as a result of new information, future events or changes in expectations. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 23 | 5,215 | 3,653 |
0000051434-25-000060#s5505 | Number Description 99.1 International Paper Company Press Release dated August 21, 2025. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 24 | 5,505 | 5,593 |
0000051434-25-000060#s5594 | 104 The cover page from this Current Report on Form 8-K, formatted as inline XBRL. | 0000051434-25-000060 | International Paper 8-K 2025-08-21 | 25 | 5,594 | 5,676 |
0000950170-24-059539#s57 | On May 14, 2024, Tenaya Therapeutics, Inc. (“Tenaya”) issued a press release announcing Tenaya’s financial results for the quarter ended March 31, 2024 (“the Earnings Press Release”). | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 0 | 57 | 240 |
0000950170-24-059539#s241 | The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 1 | 241 | 176 |
0000950170-24-059539#s361 | All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securit... | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 2 | 361 | 797 |
0000950170-24-059539#s859 | On May 14, 2024, Tenaya announced cost containment measures, including a committed plan to reduce its workforce (the “Workforce Reduction”). | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 3 | 859 | 999 |
0000950170-24-059539#s1000 | The cost containment measures align with Tenaya’s focus on generating data from its clinical-stage gene therapy programs. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 4 | 1,000 | 980 |
0000950170-24-059539#s1122 | Employees impacted by the Workforce Reduction were notified on May 13, 2024, and represent approximately 22% of the workforce. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 5 | 1,122 | 1,248 |
0000950170-24-059539#s1249 | In connection with the Workforce Reduction, Tenaya estimates that it will incur approximately $1.3 million to $1.5 million, of aggregate charges, primarily related to employee cash severance and continuing health benefits, which costs are expected to be substantially recognized during the second quarter of 2024. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 6 | 1,249 | 1,435 |
0000950170-24-059539#s1563 | The foregoing estimates that Tenaya expects to incur in connection with the Workforce Reduction are contingent upon various assumptions and actual results may differ. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 7 | 1,563 | 1,729 |
0000950170-24-059539#s1730 | Tenaya may also incur additional costs not currently contemplated due to events related to or resulting from the Workforce Reduction. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 8 | 1,730 | 1,696 |
0000950170-24-059539#s1864 | A copy of the press release announcing the cost containment measures is attached as Exhibit 99.1 to this Current Report on Form 8-K. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 9 | 1,864 | 1,996 |
0000950170-24-059539#s2026 | This Current Report on Form 8-K contains forward-looking statements, including statements regarding the continued development of Tenaya’s clinical-stage gene therapy programs and the implementation of the Workforce Reduction, including expected charges relating thereto and the objectives and anticipated timing thereof. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 10 | 2,026 | 2,346 |
0000950170-24-059539#s2347 | Actual results may differ from those set forth in or implied by this Current Report on Form 8-K due to the risks and uncertainties associated with Tenaya’s ability to conduct clinical trials of TN-201 and TN-401 sufficient to achieve a positive completion; risks related to the potential failure of TN-201 and TN-401 to ... | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 11 | 2,347 | 2,951 |
0000950170-24-059539#s3273 | You are cautioned not to place undue reliance on these forward-looking statements. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 12 | 3,273 | 2,108 |
0000950170-24-059539#s3356 | Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and Tenaya specifically disclaims any obligation to update any forward-looking statement, except as required by law. | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 13 | 3,356 | 2,252 |
0000950170-24-059539#s3656 | Description 99.1 Press Release of Tenaya Therapeutics, Inc., dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) | 0000950170-24-059539 | Tenaya Therapeutics 8-K 2024-05-14 | 14 | 3,656 | 3,811 |
0001193125-22-167332#s63 | On May 31, 2022, the board of directors (the “Board”) of Verrica Pharmaceuticals Inc. (the “Company”), in order to streamline operations and reduce costs, approved a plan to reduce its workforce by terminating 20 employees, which the Company expects to be completed by June 3, 2022. | 0001193125-22-167332 | Verrica Pharmaceuticals 8-K 2022-06-03 | 0 | 63 | 345 |
0001193125-22-167332#s346 | The decision followed the Company’s announcement on May 24, 2022 of the receipt by the Company of a complete response letter for its new drug application for VP-102. | 0001193125-22-167332 | Verrica Pharmaceuticals 8-K 2022-06-03 | 1 | 346 | 228 |
0001193125-22-167332#s512 | As a result, the Company expects to incur a one-time charge totaling approximately $0.5 million in connection with one-time employee termination costs. | 0001193125-22-167332 | Verrica Pharmaceuticals 8-K 2022-06-03 | 2 | 512 | 663 |
0001193125-22-167332#s664 | The Company expects such costs to be the only direct expense of the restructuring plan. | 0001193125-22-167332 | Verrica Pharmaceuticals 8-K 2022-06-03 | 3 | 664 | 599 |
0001193125-22-167332#s752 | This charge is expected to be incurred during the quarter ending June 30, 2022, with related cash payments expected to be substantially paid out by June 30, 2022. | 0001193125-22-167332 | Verrica Pharmaceuticals 8-K 2022-06-03 | 4 | 752 | 674 |
0001193125-22-167332#s915 | The estimates of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions and actual results may differ. | 0001193125-22-167332 | Verrica Pharmaceuticals 8-K 2022-06-03 | 5 | 915 | 1,064 |
0001213900-23-008435#s63 | On February 1, 2023, Cyren Ltd. (the “Company”) approved a plan to reduce the workforce of the Company and its subsidiaries by approximately 121 employees in the aggregate, representing substantisally all of the Company’s and its subsidiaries’ total global workforce. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 0 | 63 | 330 |
0001213900-23-008435#s331 | This decision was based on cost-reduction initiatives intended to reduce operating expenses. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 1 | 331 | 155 |
0001213900-23-008435#s424 | The Company currently estimates that it will incur one-time cash charges of a maximum of up to approximately $3,600,000.00 in connection with the reduction in force, primarily consisting of accrued paid time off, notice period payments, employee benefits and related costs. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 2 | 424 | 697 |
0001213900-23-008435#s698 | The Company expects the majority of charges will be incurred in the first quarter of 2023, subject to local law requirements, which may extend the process beyond the first quarter 2023 in certain countries. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 3 | 698 | 630 |
0001213900-23-008435#s905 | The charges the Company expects to incur are subject to assumptions, including local law requirements and availability of funds to satisfy payment obligations, and actual charges may differ from the estimate disclosed above. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 4 | 905 | 648 |
0001213900-23-008435#s1130 | A copy of the press release issued by the Company on February 1, 2023 announcing the reduction in force is attached hereto as Exhibit 99.1 and incorporated herein by reperence. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 5 | 1,130 | 1,306 |
0001213900-23-008435#s1357 | Information Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the federal securities laws. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 6 | 1,357 | 1,513 |
0001213900-23-008435#s1514 | These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 7 | 1,514 | 1,529 |
0001213900-23-008435#s1687 | These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 8 | 1,687 | 1,501 |
0001213900-23-008435#s1832 | Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 9 | 1,832 | 1,531 |
0001213900-23-008435#s2007 | While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 10 | 2,007 | 1,574 |
0001213900-23-008435#s2225 | There are many risks and uncertainties that could cause actual results to differ materially from forward-looking statements made herein including the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s Quarterly Report on Fo... | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 11 | 2,225 | 1,844 |
0001213900-23-008435#s2713 | Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 12 | 2,713 | 1,453 |
0001213900-23-008435#s2810 | The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 13 | 2,810 | 1,545 |
0001213900-23-008435#s2999 | If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 14 | 2,999 | 1,547 |
0001213900-23-008435#s3267 | 99.1 Press Release issued by Cyren Ltd. on February 1, 2023. | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 15 | 3,267 | 3,327 |
0001213900-23-008435#s3328 | 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). | 0001213900-23-008435 | Cyren 8-K 2023-02-06 | 16 | 3,328 | 3,408 |
0001493152-23-006122#s311 | The overall controlled environment agriculture market is also experiencing a fluctuating economy, rising costs, and the fear of recession that is delaying, reducing or eliminating capital projects. | 0001493152-23-006122 | CEA Industries 8-K 2023-02-27 | 0 | 311 | 197 |
0001493152-23-006122#s509 | Additionally, the Company faces continued supply chain, labor and inflationary issues that are impacting customers’ contract decisions and implementation. | 0001493152-23-006122 | CEA Industries 8-K 2023-02-27 | 1 | 509 | 154 |
0001493152-23-006122#s664 | As a result, the Company has taken cost saving initiatives to reduce operating expenses and to reduce its workforce so as to preserve working capital and liquidity without compromising the servicing of Company clients. | 0001493152-23-006122 | CEA Industries 8-K 2023-02-27 | 2 | 664 | 218 |
0001493152-23-006122#s1013 | Description 99.1 Press Release dated February 27, 2023, relating to cost saving initiatives 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) | 0001493152-23-006122 | CEA Industries 8-K 2023-02-27 | 3 | 1,013 | 1,180 |
0001628280-25-050671#s61 | On November 6, 2025, Kezar Life Sciences, Inc. (the “Company”) implemented a restructuring plan pursuant to which the Company will reduce its workforce by approximately 31 employees, or approximately 70%. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 0 | 61 | 265 |
0001628280-25-050671#s266 | The Company implemented this restructuring plan in connection with its previously announced evaluation of strategic alternatives. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 1 | 266 | 190 |
0001628280-25-050671#s396 | The Company estimates that it will incur cash expenditures of approximately $6.0 million, consisting primarily of one-time severance payments, benefits and other related costs. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 2 | 396 | 237 |
0001628280-25-050671#s573 | The Company expects to recognize the majority of such costs in the fourth quarter of 2025. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 3 | 573 | 151 |
0001628280-25-050671#s664 | The estimated costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions, and actual amounts may differ materially. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 4 | 664 | 221 |
0001628280-25-050671#s825 | The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 5 | 825 | 230 |
0001628280-25-050671#s995 | If required, the Company will amend this Current Report on Form 8-K at such time as its management is able in good faith to estimate the amount, or range of amounts, of these additional charges. | 0001628280-25-050671 | Kezar Life Sciences 8-K 2025-11-07 | 6 | 995 | 255 |
0001193125-25-085773#s63 | On April 17, 2025, Tempest Therapeutics, Inc. (the “Company”) adopted a plan to extend its capital resources in connection with initiating the previously announced process to explore a full range of strategic alternatives. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 0 | 63 | 285 |
0001193125-25-085773#s286 | As part of the plan, the Company will reduce its workforce by 21 of 26 full-time employees, effective April 30, 2025. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 1 | 286 | 180 |
0001193125-25-085773#s404 | The Company anticipates that key employees within this group will transition to consulting agreements and continue to be available to the Company. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 2 | 404 | 209 |
0001193125-25-085773#s551 | The Company estimates that it will incur approximately $1.5 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based compensation), with the majority of such costs to be incurred in the second quarter of ... | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 3 | 551 | 388 |
0001193125-25-085773#s877 | The estimated costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 4 | 877 | 211 |
0001193125-25-085773#s1026 | The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction, including potential impairment charges, if any. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 5 | 1,026 | 289 |
0001193125-25-085773#s1253 | However, the Company is not able to estimate the amount or range of amounts of such potential impairments as of the date of this Current Report on Form 8-K. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 6 | 1,253 | 219 |
0001193125-25-085773#s1410 | If required, the Company will amend this Current Report on Form 8-K at such time as its management is able in good faith to estimate the amount, or range of amounts, of these charges. | 0001193125-25-085773 | Tempest Therapeutics 8-K 2025-04-18 | 7 | 1,410 | 246 |
0001493152-22-003287#s268 | As a result, the Company anticipates terminating twelve (12) employees in the United States and twenty-three (23) in its Mexico offices (the “Terminations”). | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 0 | 268 | 157 |
0001493152-22-003287#s426 | As a result of the Terminations, the Company will (i) reduce its workforce by approximately seventy percent 70% in total and (ii) reduce its annual payroll by $2.09 million or approximately fifty seven percent (57%). | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 1 | 426 | 216 |
0001493152-22-003287#s643 | The Terminations, which will be effective February 15, 2022, were part of a broad set of cost-saving measures implemented by new management subsequent to the completion of its merger with BritePool, Inc. that closed on November 30, 2021. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 2 | 643 | 237 |
0001493152-22-003287#s881 | The Company estimates that the pre-tax costs for the Terminations will be in the range of $80,000 to $150,000, substantially all of which are related to employee severance (the “Severances”), which the Company expects to record in the quarter ending March 31, 2022. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 3 | 881 | 265 |
0001493152-22-003287#s1147 | The Company does not anticipate any future cash expenditures beyond the payment of the Severances. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 4 | 1,147 | 98 |
0001493152-22-003287#s1488 | These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 5 | 1,488 | 1,555 |
0001493152-22-003287#s1629 | The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 6 | 1,629 | 1,672 |
0001493152-22-003287#s1887 | In addition, the Company’s workforce reduction costs may be greater than anticipated and the workforce reduction may have an adverse impact on the Company’s development activities. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 7 | 1,887 | 1,595 |
0001493152-22-003287#s2068 | A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2021, and the Company’s subsequent cur... | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 8 | 2,068 | 2,420 |
0001493152-22-003287#s2421 | The Company undertakes no duty or obligation to update any forward-looking statements contained in this Item 2.05 as a result of new information, future events or changes in its expectations. | 0001493152-22-003287 | Bigtoken 8-K 2022-02-04 | 9 | 2,421 | 2,259 |
0001115128-22-000036#s62 | On November 15, 2022, Quotient Technology Inc. (“Quotient”) initiated a workforce reduction plan in connection with its ongoing business transformation efforts. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 0 | 62 | 222 |
0001115128-22-000036#s223 | Quotient will reduce its workforce in the United States, United Kingdom, and India across all functions by approximately 82 employees. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 1 | 223 | 196 |
0001115128-22-000036#s358 | This represents a reduction of approximately nine percent (9%) of Quotient’s regular full-time global workforce and approximately fourteen percent (14%) of Quotient’s U.S.-based workforce. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 2 | 358 | 250 |
0001115128-22-000036#s547 | In connection with this plan, Quotient estimates that it will recognize total pre-tax restructuring charges to its GAAP financial results in the approximate amount of $2 million consisting of severance and other one-time termination benefits. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 3 | 547 | 789 |
0001115128-22-000036#s827 | Quotient expects that these charges will be recognized in the fourth quarter of fiscal 2022. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 4 | 827 | 639 |
0001115128-22-000036#s920 | The foregoing contains forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 5 | 920 | 1,075 |
0001115128-22-000036#s1076 | These forward-looking statements include the amount of, and timing of, workforce-related charges and the status of Quotient’s business transformation efforts. | 0001115128-22-000036 | Quotient Technology 8-K 2022-11-16 | 6 | 1,076 | 1,078 |
EDGAR 8-K — Context Chunk Retrieval (coreference + near-duplicate)
A contextualized sentence-level (query2chunk) retrieval eval built from SEC 8-K restructuring filings (EDGAR), for the Chunk-level Retrieval Eval collection.
Why this benchmark exists. Standard passage benchmarks (e.g. DAPR) don't discriminate contextual embedding models, because their answer passages already contain the distinguishing entity and have no near-duplicate distractors. This dataset is built to stress document-context disambiguation:
- Sentence chunks are coreference-dependent — the answer sentence says "the Company", never the company name, so resolving it requires the surrounding document.
- Near-identical distractors across companies — 8-Ks are templated, so the corpus holds dozens of near-identical sentences like "the Company estimates that it will incur charges of approximately $X million" differing only by amount/company. In isolation these are indistinguishable; only the document context resolves which "Company" is meant.
Example — query "What restructuring charges does Elastic expect to incur?" → answer "The Company expects to incur total non-recurring cash charges of approximately $22 million to $25 million…" competes against 58 near-identical charge sentences from other filings.
Stats
| count | |
|---|---|
| documents (filings) | 246 |
| corpus (sentence chunks) | 4,936 |
| queries | 38 (28 with a supporting-evidence fragment) |
| near-duplicate charge sentences | 58 |
| near-duplicate workforce sentences | 53 |
Graded gold: answer vs supporting evidence
Gold is graded via the standard score field (no schema change vs the rest of the
collection):
score |
role | meaning |
|---|---|---|
| 2 | answer |
the sentence that directly answers the query (uses coreference) |
| 1 | evidence |
a supporting fact that disambiguates the answer (e.g. the sentence binding the company name to "the Company") |
Derive the two metrics from one qrels:
standard_recall@k = |topk ∩ {score >= 2}| / |{score >= 2}| # answer only
evidence_recall@k = |topk ∩ {score >= 1}| / |{score >= 1}| # answer + supporting evidence
nDCG@k can consume the graded scores directly. A human-readable roles field
(answer / evidence) mirrors the score. Backward compatible: datasets that use
score = 1 uniformly are answer-only (no evidence tier).
Configs
documents
chunk_id, chunk (one sentence), source_url (filing accession — group chunks by this
to give a contextual model its document view), title (company + 8-K date),
chunk_idx (sentence position in the filing), chunk_start_char / chunk_end_char.
queries
original_query / query, answer[] (gold sentence texts), score[] (2=answer, 1=evidence),
source_url[] (filing per gold), frag_start_char[] / frag_end_char[], n_gold,
roles[] (answer/evidence), fact (workforce / charges).
Gold matching: a chunk is gold for a query if it shares source_url and its
[chunk_start_char, chunk_end_char) overlaps a gold fragment's span (each gold maps to
exactly one sentence chunk).
Construction & limitations
Built from EDGAR full-text search for restructuring 8-Ks (2022–2026), one primary filing per company. HTML cleaned (inline-XBRL/hidden/exhibit boilerplate stripped, sliced to the Item narrative), sentence-split with NLTK Punkt, junk/heading/fragment chunks removed.
- Prototype scale — 38 queries; the query set skews toward
charges(workforce answers more often repeat the company name and are filtered out to preserve the coreference axis). - Templated queries — 2 regex-generated templates (
workforce,charges); phrasing overlaps the gold, so the difficulty is the coreference/near-duplicate disambiguation, not the wording. A natural/LLM-generated query pass is future work. - Evidence coverage — 28/38 queries have a supporting-evidence fragment; the rest are answer-only.
Source: public SEC EDGAR filings (U.S. government works / public domain).
- Downloads last month
- 11